drugset / Trial / NCT01769183

Squalamine for the Treatment in Proliferative Diabetic Retinopathy

NCT01769183

Phase 2 Completed 6 enrolled Elman Retina Group
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy in the use of topical Squalamine Lactate Ophthalmic Solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.

Timeline

Start
2013-02
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Squalamine Unknown 0.2 % Topical